Observational analysis reveals neuroinflammation in GAD65 antibody-associated epilepsy, suggesting new therapeutic timing.
The timing for initiating immunotherapy in patients with glutamic acid decarboxylase 65 (GAD65) antibody‐associated epilepsy is a challenge. We used the translocator protein radioligand [ 18 F]DPA‐714 and PET to evaluate brain microglial activation. [ 18 F]DPA‐714 PET brain images of 11 patients with GAD65 antibody‐associated epilepsy and seven controls were analyzed. Patients with acute symptomatic seizures presented higher [ 18 F]DPA‐714 SUVR in the hippocampus than did controls and patients with chronic temporal lobe epilepsy. Our findings highlight that [ 18 F]DPA‐714 PET/MRI represents a useful tool to assess neuroinflammation in patients with GAD65 antibody‐associated epilepsy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: